secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001200375-24-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q1 revenue up 32%, net loss narrows to $11.5M; reiterates FY guidance
-----------------------------------------------------------------------------

- Total revenue $17.1M (+32% YoY); product revenue $9.6M (+14%); net loss $11.5M vs $22.6M loss in Q1 2023.
- Received first large pharma order for dsRNA ligase (low-to-mid single digit million) and entered $40M loan facility with Innovatus.
- Reiterated FY 2024 guidance: product rev $38-42M, R&D rev $18-22M, product gross margin 58-63%.
- Cash and investments $85.5M; expects to fund operations through positive cash flow by end of 2026.
- Exclusive license with Roche for dsDNA ligase; sold HCU and MSUD compounds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/0001200375-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037524000013/cdxs-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001200375-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer